ExploreWatchlistsPricing
  1. JP-listed companies
  2. StemRIM Inc.
  3. Financials
  4. Earnings per share

StemRIM Inc. (4599)

Market cap
¥19.3B
P/E ratio
StemRim develops regenerative induction pharmaceuticals that activate patients' own stem cells to repair damaged tissues using peptide-based drugs like Ledasemdide.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndEarnings per share (JPY)YoY (%)
Jul 31, 2025-31.2-5.52%
Jul 31, 2024-33-1277.86%
Jul 31, 20232.8-108.51%
Jul 31, 2022-32.9+228.54%
Jul 31, 2021-10-255.59%
Jul 31, 20206.4-138.22%
Jul 31, 2019-16.8+98.94%
Jul 31, 2018-8.5+142.00%
Jul 31, 2017-3.5-100.21%
Jul 31, 20161,703.4-274.51%
Jul 31, 2015-976.1

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat